CGT · BCMA

92개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved92 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTCurated CoreFDAstaleJohnson & JohnsonApproved

ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528)

Relapsed or refractory multiple myeloma · BCMA

#BCMA#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 29Status Approved
CGTLimited DatastaleThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 211Status Discontinued
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 131Status Active
CGTLimited DatastaleMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTLimited DatastaleCarbiogene Therapeutics Co. Ltd.Phase 2

anti-BCMA CAR-T (anti-BCMA CAR-T)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Recruiting
CGTLimited DatastalePoseida Therapeutics, Inc.Phase 2

autologous anti-BCMA chimeric antigen receptor T cells (autologous anti-BCMA chimeric antigen receptor T cells)

ITP · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 47Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 2

BCMA CAR-T (BCMA CAR-T)

Multiple Myeloma, Newly Diagnosed · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 35Status Recruiting
CGTLimited DatastaleEssen BiotechPhase 2

CD19/BCMA CAR T-cells (CD19/BCMA CAR T-cells)

Systemic Lupus Erythematosus; Lupus Nephritis · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 32Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 30Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

Autologous BCMA CAR-T cells and CD19 CAR-T cells (Autologous BCMA CAR-T cells and CD19 CAR-T cells)

Relapsed or Refractory Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 2

Autologous BCMA-targeting CAR T cells (Autologous BCMA-targeting CAR T cells)

Multiple Myeloma in Relapse; Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

BCMA-CART cells (BCMA-CART cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Active
CGTLimited DatastaleGracell Biotechnology Ltd.Phase 1

BCMA/CD19 Dual-Target CAR-T (BCMA/CD19 Dual-Target CAR-T)

Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 27Status Active
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

T cell infusion agent targeting BCMA chimeric antigen receptor (T cell infusion agent targeting BCMA chimeric antigen receptor)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 13Status Active
CGTLimited DatastaleXi'niao BiotechPhase 1

universal allogeneic anti-CD19/BCMA CAR T-cells (universal allogeneic anti-CD19/BCMA CAR T-cells)

Autoimmune Hemolytic Anemia; CD19/BCMA CAR T-cells · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 12Status Recruiting
CGTLimited DatastaleAsclepius Technology Company Gr…Phase 1

Anti-BCMA CAR-NK Cells (Anti-BCMA CAR-NK Cells)

Multiple Myeloma, Refractory · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 10Status Active
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Phase 2

Eque-cel (Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection, Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel))

Relapsed/Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 9Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

BCMA-CD19 cCAR T cells (BCMA-CD19 cCAR T cells)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 5Status Recruiting
CGTLimited DatastaleThe Children's Hospital of Zhej…Phase 1

KN5601 (anti-CD19/BCMA CAR NK cells, anti-CD19/BCMA CAR NK cells (KN5601))

Autoimmune Diseases; Systemic Lupus Erthematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 5Status Recruiting
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

Assigned Interventions CD19/BCMA CAR T-cells (Assigned Interventions CD19/BCMA CAR T-cells)

Systemic Lupus Erythematosus; Autoimmune Diseases · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 4Status Active

1 / 5 pages

← PreviousNext →